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Abstract
Trastuzumab is associated with cardiotoxicity, manifesting as a decrease of the left-ventricular ejection fraction (LVEF).
Administration of anthracyclines prior to trastuzumab increases risk of cardiotoxicity. High-sensitive troponin T and
N-terminal-pro-brain natriuretic peptide (NT-proBNP) are molecular markers that may allow earlier detection of drug-
induced cardiotoxicity. In this analysis we aimed to quantify the kinetics and exposure–response relationships of LVEF,
troponin T and NT-proBNP measurements, in patients receiving anthracycline and trastuzumab. Repeated measurements of
LVEF, troponin T and NT-proBNP and dosing records of anthracyclines and trastuzumab were available from a previously
published clinical trial. This trial included 206 evaluable patients with early breast cancer. Exposure to anthracycline and
trastuzumab was simulated based on available dosing records and by using a kinetic-pharmacodynamic (K-PD) and a fixed
pharmacokinetic (PK) model from literature, respectively. The change from baseline troponin T was described with a direct
effect model, affected by simulated anthracycline concentrations, representing myocyte damage. The relationship between
trastuzumab and LVEF was described by an indirect effect compartment model. The EC50 for LVEF decline was sig-
nificantly affected by the maximum troponin T concentration after anthracycline treatment, explaining 15.1% of inter-
individual variability. In this cohort, NT-proBNP changes could not be demonstrated to be related to anthracycline or
trastuzumab treatment. Pharmacodynamic models for troponin T and LVEF were successfully developed, identifying
maximum troponin T concentration after anthracycline treatment as a significant determinant for trastuzumab-induced
LVEF decline. These models can help identify patients at risk of drug-induced cardiotoxicity and optimize cardiac
monitoring strategies.
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Introduction
Trastuzumab is a monoclonal antibody that targets the
human epidermal growth factor receptor 2 (HER2) and is
used to treat HER2-positive metastatic and early breast
cancer and metastatic gastric cancer [1–3]. Despite
improvement in overall and progression free survival,
application of the drug is hampered by cardiac adverse
effects, leading to dose reductions, dose-delays and treat-
ment interruption or withdrawal with an increased recur-
rence risk as a consequence [4]. Trastuzumab-induced
cardiotoxicity is manifested as an asymptomatic decrease
of the left-ventricular ejection fraction (LVEF) and
development of congestive heart failure [5]. The mecha-
nism behind this cardio-toxic effect is not completely
elucidated, though it has been demonstrated that trastuzu-
mab causes structural and functional changes to contractile
proteins in the heart muscle [6, 7]. These changes rarely
lead to cell death, that might explain why the decrease in
LVEF values is partly reversible when trastuzumab treat-
ment is discontinued [5]. In addition, patients treated with
trastuzumab are often pretreated with anthracyclines.
Anthracyclines can irreversibly damage myocytes, possibly
by generation of reactive oxygen species and lipid perox-
idation of the cell membrane of cardiomyocytes [8]. A
cumulative lifetime dose exceeding 550 mg/m2 for dox-
orubicin and 950 mg/m2 for epirubicin has been associated
with increased incidence of heart failure [9, 10]. These
cumulative dose thresholds are therefore clinically applied
to limit the risk for cardiac damage. Since both trastuzu-
mab and anthracyclines can lead to cardiac dysfunction, it
is not surprising that a higher incidence of cardiac dys-
function has been reported for patients treated with
anthracyclines concomitantly or prior to trastuzumab [11].
However, a high variability in susceptibility to cardiotox-
icity is seen for patients treated with anthracyclines and
trastuzumab. Cardiac function can be monitored during
treatment using echocardiography or multiple gated
acquisition (MUGA) scan to determine the LVEF.
Attempts have been made to optimize cardiac monitoring
strategies, allowing for a better identification of patients
that experience cardiotoxicity and decrease the number of
LVEF measurements in low-risk patients [12]. Cardiac
biomarkers such as troponin T and N-terminal-pro-brain
natriuretic peptide (NT-proBNP) are molecular markers
suggested to allow earlier detection of drug-induced car-
diotoxicity compared to LVEF measurement [13]. Cardiac
troponins are indicative of myocyte damage and are sug-
gested to predict patients at risk of cardiotoxicity during
trastuzumab treatment who are pretreated with anthracy-
clines [14]. In addition, elevated baseline concentrations of
troponin I and troponin T have been related to an increased
risk of LVEF decrease [13]. NT-proBNP is a marker for
heart failure. Currently, troponins and NT-proBNP are used
as cardiac biomarkers for prognosis and diagnosis of
myocardial infarction and heart failure, respectively [15].
However, no evidence exists for anti-cancer drug man-
agement based on abnormal cardiac biomarker concentra-
tions. Development of a pharmacokinetic–
pharmacodynamic (biomarker) model can give insight in
the time course of cardiac biomarkers during treatment and
help identify the optimal time point of cardiac biomarker
assessment. In this analysis, we aim to quantify the kinetics
and exposure–response relationship of LVEF, troponin T
and NT-proBNP measurements, in patients with early
breast cancer receiving anthracyclines followed by trastu-
zumab. Ultimately, the quantification of cardiac biomark-
ers could help identify patients at increased risk of
developing cardiotoxicity and optimize clinical manage-
ment of trastuzumab-induced cardiotoxicity.
Methods
Patients and data
The analysis conducted in this study was based upon data
from patients with HER2-positive early breast cancer from
a previously conducted randomized, placebo-controlled
clinical trial, investigating protection for trastuzumab-in-
duced cardiotoxicity with angiotensin II-receptor inhibitor
candesartan. All patients received adjuvant treatment with
anthracycline-containing chemotherapy, either doxoru-
bicine or epirubicine, followed by trastuzumab treatment
for 52 weeks. Patients were randomized to receive can-
desartan or placebo (1:1) daily, starting from the first
trastuzumab administration until 26 weeks after the last
trastuzumab administration. The trial demonstrated that
concomitant candesartan treatment did not protect against
decreases in LVEF during trastuzumab treatment. [16]
Repeated measurements for LVEF were available for all
patients. LVEF was determined with MUGA scan or
echocardiography. Autologous red blood cells (400 MBq
Tc-99m labelled) were injected and acquisition was per-
formed in 6 min with a large-field-of-view gamma camera
with a low energy all-purpose parallel-hole collimater.
Troponin T and NT-proBNP concentrations were available
for 92% of patients and were measured in plasma samples
using a sandwich immunoassay (Modular E system, Roche
Diagnostics). The lower-limit of quantification (LLOQ) for
NT-proBNP was 5 pg/mL and for (high sensitive) troponin
T 3 ng/L. Troponin T and NT-proBNP measurements were
scheduled at the following visits: before starting anthra-
cycline treatment, at baseline before starting trastuzumab
treatment and 3, 12, 24, 36, 52, 64, 78 and 92 after starting
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trastuzumab treatment. LVEF was evaluated at the same
time points, except for the 3 week and 64 week visit since
start trastuzumab treatment. Additionally, individual
patient dosing records, including time of administration
and dosages of anthracycline and trastuzumab were avail-
able. None of the patients received a cumulative dose
above 550 or 950 mg/m2 for doxorubicin and epirubicin,
respectively.
Modeling cardiac biomarkers
Structural models
Exposure to anthracyclines and trastuzumab were predicted
using individual dosing records of the drugs and simulated
using different approaches. A K-PD approach was applied
for the anthracyclines (doxorubicin and epirubicin) [17].
The trastuzumab PK profiles were obtained using fixed
effect parameters from a previously published PK model
for HER2-positive breast cancer patients [18].
Exploratory plots were used to determine pharmacody-
namic modeling starting points for the three cardiac
biomarkers. The plots demonstrated an increase in troponin
T during anthracycline treatment, and a gradual decrease of
troponin T during trastuzumab treatment. Therefore, tro-
ponin T changes were assumed to be related to anthracy-
cline treatment only. Troponin T samples were taken
before anthracycline treatment, approximately 21 days
after the last anthracycline dose and during trastuzumab
treatment, with limited samples available during anthra-
cycline treatment. Therefore, direct and indirect effect
models were evaluated to identify if the troponin T peak
concentration occurred right after the last administration of
anthracyclines or if the peak was delayed after treatment.
A previously published model by our group was used as
a starting point for modeling trastuzumab-induced LVEF
decrease [19]. In this model the LVEF decline was
described by an effect compartment, demonstrating cardiac
damage induced by trastuzumab treatment. The delay in
LVEF decline in relation to trastuzumab treatment (the
cardiac damage onset rate) was kept equal to the rate of
recovery.
NT-proBNP changes were evaluated during anthracy-
cline and trastuzumab treatment separately. A model that
described NT-proBNP concentrations to be inversely
associated with LVEF values was evaluated. In addition,
NT-proBNP baseline values prior to initiation of either
anthracycline or trastuzumab treatment were evaluated as
covariates.
Statistical models
Between subject variability (BSV) was evaluated for all
structural model parameters using an exponential error
model:
Pi ¼ Ppop  exp gið Þ
where Pi is the individual parameter estimate for individual
i, Ppop the population parameter estimate and gi the indi-
vidual value of between-subject variability for subject i,
where gi was assumed to be normally distributed with
mean 0 and variance x2. Off-diagonal elements of the
variance–covariance (omega) matrix, were evaluated to
identify covariances between the individual random
effects. These covariances were used to derive the corre-
lations between the random-effects. Residual unexplained
variability was described as a proportional error model for
all cardiac biomarkers:
Cobs;ij ¼ Cpred;ij  1 þ ep;ij
 
where Cobs;ij represents the observed concentration for
individual i and observation j, Cpred;ij represents the indi-
vidual predicted concentration, ep,ij the proportional error
distributed following N (0,r2).
Covariate analysis
Different covariates were included in the covariate analy-
sis, based on physiological plausibility and clinical rele-
vance. The following covariates were evaluated for the
anthracycline-troponin T model and the trastuzumab-LVEF
model: age, hypertension diagnosis and status, radiotherapy
of the chest, laterality of radiotherapy and type of anthra-
cycline administered. Additionally, type of anthracycline
(epirubicin or doxorubicin) was evaluated as a covariate for
the anthracycline-troponin T model, and baseline LVEF
values (prior to initiation of trastuzumab) and time between
last anthracycline dose and first trastuzumab dose for the
trastuzumab-LVEF model. Since patients in this cohort
were randomized to receive either placebo or candesartan
to prevent or alleviate trastuzumab-induced cardiotoxicity,
treatment group was evaluated as a covariate. In addition,
the dose normalized cumulative dose of anthracycline and
the predicted maximum concentration of troponin T
reached by the previous anthracycline treatment were
evaluated as a covariates. Binary covariates (previous
radiotherapy, hypertension diagnosis, type of anthracycline
administered) were implemented using the following
equation:
Pi ¼ Ppop  hcovð ÞCOV
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where hcov is the covariate effect parameter and COV the
covariate value. Continuous covariates (COVcont) (time
between last anthracycline dose and initiation of trastuzu-
mab, maximum concentrations of troponin T) were nor-
malized to the median value of the covariate (COVmedian)
and implemented as follows:
Pi ¼ Ppop  COVcont
COVmedian
 hcov
Categorical covariates (laterality of radiotherapy and
hypertension status) were implemented by estimating a
separate parameter for each category. The selected physi-
ologically plausible and clinically relevant covariates were
evaluated using a forward inclusion and backward elimi-
nation method. A significance level of p\ 0.01 was set for
the forward inclusion, corresponding to a decrease of OFV
of[ 6.63. For backward elimination, a significance level
of p\ 0.005 was set, corresponding to an increase of OFV
of[ 7.88.
Model evaluation
Models evaluation was performed using general goodness-
of-fit (GOF) plots, plausibility, stability and precision of
parameter estimates and change in objection function value
(OFV) [20]. A p\ 0.01 was considered significant,
meaning that an OFV drop of[ 6.63 for hierarchical
models (degree of freedom = 1, Chi squared distribution)
was considered as a significant improvement. Since tro-
ponin T samples were taken predominantly before anthra-
cycline treatment and approximately 21 days after the last
anthracycline dose, predicted troponin T concentrations at
day 21 after the last anthracycline administration were also
evaluated as a covariate. In addition, the final model for
LVEF was evaluated for the placebo and the candesartan
group, separately, in order to identify possible differences
related to study treatment.
Software
Data management and graphical evaluation were per-
formed using R (version 3.0.1) [21]. Nonlinear mixed
effects modeling was performed using NONMEM (version
7.3.0, ICON Development Solutions, Ellicott City, MD,
USA) and Perl-speaks-NONMEM (version 4.4.8) [22, 23].
Piran˜a (version 2.9.2) was used as graphical user interface
[24]. Models were estimated using First Order Conditional
Estimation method with g–e interaction (FOCE-I).
Results
Patients and data
In the final analysis, 206 patients were included. A total of
1444 LVEF measurements (96% by MUGA scan) were
available for 206 patients with a median [range] of 8 [2–9]
measurements per patient. Troponin T and NT-proBNP
measurements were available for 190 patients, with a total
of 1230 troponin T measurements, 7 [1–11] measurements
per patient, and 1028 NT-proBNP measurements, 6 [1–10]
measurements per patient. Concentrations below the LLOQ
were divided by two in the final dataset (4.6% of the tro-
ponin T observations and 2.5% of NT-proBNP were below
the LLOQ). Part of the patient characteristics are depicted
in Table 1. The clinical data have been extensively
described elsewhere [16].
Data and models for the cardiac biomarkers troponin T,
LVEF, and NT-proBNP were explored separately in rela-
tion to the anthracycline concentration–time profiles (tro-
ponin T and NT-proBNP) and to the trastuzumab
concentration–time profiles (LVEF and NT-proBNP). The
final model parameter estimates are summarized in
Table 2.
Troponin T
Troponin T changes were best described by a direct effect
model, where the troponin T concentration increased pro-
portionally with the increment of simulated anthracycline
concentrations (Fig. 1a). The model was described by the
following equations:
dAant
dt
¼ Ke  Aant
TRP ¼ TRP0  ð1 þ SLOPE  AantÞ
where Aant is the amount of anthracyclines, Ke the elimi-
nation rate constant, TRP is troponin T, TRP0 is troponin T
at baseline, before starting anthracycline treatment, SLOPE
is the parameter that describes the proportional increase of
troponin T from baseline. The goodness of fit plots (Fig. 2a
and Online Resource 1 Fig. S1) showed that the anthra-
cycline-troponin T underpredicted some of the observed
higher concentration of troponin T. However, the individ-
ual predictions were considered adequate. The VPC
showed a slight overprediction of the declining troponin T
concentrations in the 95th percentile (Fig. 3), nevertheless,
the higher concentrations are described adequately. NPDE
plots did not show significant trends. In addition, an indi-
rect effect model was evaluated. However, this model
underpredicted the observed concentrations around day 21
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post last anthracycline dose and also underpredicted the
recovery rate of the troponin T peak.
LVEF
The previously published LVEF model, used as a modeling
starting point, described the data well [19]. However,
different models were evaluated to separate the delay in
cardiac damage after trastuzumab administration and the
recovery rate. In the final model, the cardiac damage was
generated by cumulative trastuzumab concentrations and
the recovery half-life was estimated. The structural model
is depicted in Fig. 1b. The model was described by the
following equations:
Table 1 Patient characteristics
Median [range] N
Age at randomization (years) 50 [25–69] –
Number of anthracycline cycles 4 [2–6] –
Absolute doses of anthracyclines
Doxorubicin (mg) 110 [75–150] –
Epirubicin (mg) 170 [100–200] –
Number of trastuzumab cycles 23 [5–46] –
Trastuzumab doses
3 weekly schedule 8–6 mg/kg 62
Weekly schedule 4–2 mg/kg 144
Time between last anthracycline dose and first trastuzumab dose (days) 21 [14–217]
No. of patients (n = 206) %
Measurements
LVEF measurements available 206 100
LVEF baseline—before anthracycline 173 84.0
LVEF baseline—before trastuzumab 205 99.5
Troponin T measurements available 190 92.2
NT-proBNP measurements available 190 92.2
Type of anthracycline treatment
Doxorubicin 181 87.9
Epirubicin 25 12.1
Clinically relevant decline in LVEFa
Yes 37 18
No 169 82
Medical history
Previous radiotherapy
Yes 112 45.6
No 94 54.4
Laterality of radiotherapy
Left 58 28.2
Right 54 26.2
No radiotherapy 94 45.6
Hypertension ever diagnosed
Yes 24 11.7
No 182 88.3
Hypertension status
Past 5 2.4
Dormant 12 5.8
Active 7 3.4
No hypertension 182 88.3
aA decline in LVEF was assumed clinically relevant if LVEF values decreased with 15% or more from
baseline or if a value of\ 45% was reached
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Table 2 Parameter estimates for cardiac biomarker models anthracycline-troponin T and trastuzumab-LVEF
Parameter Unit Parameter estimate RSE (%) Shrinkage (%)
Anthracycline—troponin T model
Troponin T baseline (TRP0) ng/L 4.72 3.5 –
Elimination rate constant K-PD model (ke) Day
-1 8.49 9 10-3 4.0 –
Proportional effect (anthracyclines-troponin T) (SLOPE) ng-1 L 8.84 9 10-3 7.0 –
Proportional anthracycline-type effect on SLOPE 0.524 17.5 –
Between-subject variability (%)
Slope effect on TRP0 (SLOPE) CV 57.7 23.3 31.0
Troponin T baseline (TRP0) CV 39.2 9.9 12.6
Residual variability
Proportional residual error troponin T % 30.1 4.2 11.2
Trastuzumab—LVEF model –
LVEF baseline value (LVEF0) 0.599 0.6 –
Recovery half-life (T1/2rec) Day 67.9 17.2 –
Sensitivity to LVEF decline (EC50) mg/L 2.18 9 10
5 23.4 –
Maximum troponin T effect on EC50 - 1.16 23.4 –
Between-subject variability (%)
LVEF baseline value (LVEF0) CV 7.07 16.7 9.9
Sensitivity to LVEF decline (EC50) CV 82.9 43.1 26.0
Correlation xLVEF0 xEC50 a – 0.585
Residual variability
Proportional residual error LVEF % 7.8 2.9 8.3
CV coefficient of variation, SD standard deviation, RSE relative standard error
aCorrelation derived from the variance–covariance matrix of the random effects
Fig. 1 Structural models for
anthracycline and troponin T
(K-PD) and trastuzumab and
LVEF (PK-PD),
Ke = elimination rate constant,
Aant = amount of
anthracyclines, Ceff = the
concentration in the effect
compartment, Krec = recovery
rate constant, T1/2rec = recovery
half-life
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Fig. 2 Diagnostic plots for a troponin T and b left ventricular ejection fractions (LVEF), including individual and population predictions and
normalized prediction distribution error (NPDE) over predictions and time
Fig. 3 Prediction corrected visual predictive checks (pcVPCs) for
troponin T and left ventricular ejection fractions (LVEF). The solid
line represents the median of the observed data, the dashed lines
represent the 5th and 95th percentiles of the observed data, the shaded
areas represent the 95% confidence interval of the simulated data for
the corresponding percentiles (n = 500)
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dCeff
dt
¼ Ctrastuzumab  ln 2ð Þ
T1=2rec
 
 Ceff
LVEF ¼ LVEF0  1  Ceff
Ceff þ EC50
 
where Ceff is the effect compartment concentration,
Ctrastuzumab the trastuzumab concentration in the central
compartment, T1/2rec the recovery half-life (where
lnð2Þ=T1=2rec represents the recovery rate constant), LVEF0
the LVEF baseline value before the first administration of
trastuzumab and EC50 the concentration at which 50% of
the drug effect occurs. LVEF decline recovered after ces-
sation of trastuzumab treatment with a recovery half-life of
68 days (RSE 17.2%). The BSV for both EC50 and
recovery could not be identified, therefore the BSV on
recovery was not included in the final model. The BSV in
baseline LVEF was moderately positively correlated with
the EC50 parameter (r = 0.585), indicating that patients
with a low baseline LVEF tend to have a higher sensitivity
to trastuzumab-induced LVEF decline (lower EC50). The
model described the data adequately, however a slight
underprediction was seen for the lower LVEF values
(Fig. 2B, Fig. 3 and Online Resource 1—Fig. S1). This is
expected to be the result of discontinuation of treatment in
patients experiencing a significant decrease in LVEF, for
whom follow up LVEF measurements were not available
(e.g. Fig. 4a, c). Therefore, the recovery to baseline in
these patients was not supported by observations, but was
predicted by the model. A decrease in LVEF was classified
as significant if LVEF dropped below 45% or when a
decrease of 15% from baseline occurred. The final model
was evaluated for the candesartan and placebo group sep-
arately. No mayor differences were found in magnitude of
parameter estimates or model fit, as expected (data not
shown).
NT-proBNP
NT-proBNP did not demonstrate a clear trend over time
during anthracycline or trastuzumab treatment and NT-
proBNP concentrations did not increase before LVEF
decline occurred and did not behave as an inverse of LVEF
decline. Therefore, the NT-proBNP baseline concentrations
were evaluated as covariates in the LVEF model. These
models were also evaluated for each treatment group sep-
arately (candesartan and placebo), leading to similar
results. However, high relative increases of NT-proBNP,
approximately 27 weeks after the lowest LVEF value, were
observed in 4 patients with a significant decline in LVEF
and in 3 patients with no significant decline in LVEF
(Online Resource 1, Figs. S2 and S3). NT-proBNP incre-
ment could, therefore, be a delayed effect of previous
LVEF decline, a sign of other underlying cardiac disease or
a forecast of development of congestive heart failure, since
these patients did not report an increase in heart failure
symptoms (NYHA) at the time of the peak. Therefore, NT-
proBNP was not included in the LVEF model.
Covariates
The covariates were evaluated on the SLOPE parameter
(anthracycline-troponin T model) and on the EC50 and
recovery half-life parameter (trastuzumab-LVEF model).
No covariates were identified that significantly improved
model fit of the anthracycline-troponin T model, except for
type of anthracycline on the SLOPE parameter. The
SLOPE-parameter, was significantly affected by the type of
anthracycline administered, as illustrated by twofold lower
estimate for epirubicin compared to doxorubicin (anthra-
cycline-type effect estimate of 0.524 (relative standard
error (RSE) 17.5%). This means that, for example,
administration of one dose of 100 mg doxorubicine leads
to an increase in troponin T from 3 to 5.6 ng/L, where an
equivalent dose of epirubicin would increase troponin T
from 3 to 4.3 ng/L. Considering the LVEF-trastuzumab
model, the sensitivity for LVEF decline (EC50 parameter)
was significantly affected by the predicted maximum
concentration of troponin T after anthracycline treatment.
Sensitivity for LVEF decline was higher (decreased EC50
parameter) for patients with a high maximum concentration
of troponin T, resulting in a more pronounced decline in
LVEF during trastuzumab treatment (Fig. 4), described by
the following equation:
EC50i ¼ EC50pop  TRPmax
18
 1:16
where TRPmax is the peak concentration of troponin T.
According to this equation, a peak concentration of 31 ng/
L troponin T, would increase the sensitivity to LVEF
decrease by a twofold (twofold decrease in EC50). The
maximum troponin T concentration reduced the between
subject variability in sensitivity for LVEF decline from
98.0% in the base model (Online Resource 1, Table S1) to
82.9% in the covariate model. The sensitivity analysis
demonstrated that the predicted concentration of troponin T
at 21 days after the last anthracycline dose was an equally
significant covariate on the EC50 parameter (Online
Resource 1, Table S1). The other tested covariates did not
significantly improve the model.
438 Journal of Pharmacokinetics and Pharmacodynamics (2018) 45:431–442
123
Discussion
The pharmacodynamics of troponin T and LVEF changes
during anthracycline and trastuzumab treatment, respec-
tively, were successfully described by the reported models.
The maximum concentration of troponin T was a signifi-
cant determinant of sensitivity to trastuzumab-induced
cardiotoxicity, defined as a decline in LVEF values.
Baseline troponin T concentrations were directly affec-
ted by anthracycline concentrations. The type of anthra-
cycline significantly affected the linear SLOPE parameter,
showing that epirubicin had an approximately twofold
lower proportional effect on baseline troponin T concen-
trations compared to doxorubicin. This finding is expected,
since at equivalent doses, epirubicin demonstrates less
cardiotoxicity than doxorubicin. Moreover, the cumulative
lifetime anthracycline dose threshold, associated with
increased incidence of heart failure, is also almost a two-
fold higher for epirubicin (950 mg/m2) compared to dox-
orubicin (550 mg/m2) [9, 10]. The anthracycline-troponin
T model predicted maximum troponin T concentration at
the day of the last anthracycline infusion. However most of
the troponin T samples were drawn at approximately
21 days after the last anthracycline dose. To delay the
troponin T peak to 21 days, a turnover model was evalu-
ated. However, the recovery rate of troponin T was esti-
mated to be slower than observed, indicating that the peak
of troponin T occurs earlier after administration. This is
supported by literature, reporting that myocyte damage
induced by anthracyclines occurs within hours after
administration [25]. In addition, an increase of troponin T
within 1–3 days after doxorubicin infusion has been
reported in the pediatric setting and an increase in troponin
I within hours after high-dose chemotherapy has been
reported for adults [26, 27].
The trastuzumab-LVEF model demonstrated a decline
in LVEF values that improved after treatment cessation,
demonstrated by a recovery of LVEF towards baseline.
This analysis prospectively validated the model for LVEF
developed in a previously published PK-PD analysis [19].
A high variability in susceptibility to LVEF decline and
development of congestive heart failure has been reported
Fig. 4 Panels of individual plots for observed (solid line) and
individual predicted (dotted line) left ventricular ejection fractions
(LVEFs) over time for four different patients. Vertical dashes
represent the trastuzumab administrations. a Patient with maximum
troponin T values in the higher range, relatively high baseline and a
significant decline in LVEF value. b Patient with lower maximum
concentration of troponin T, normal baseline and no significant
decline in LVEF. c Patient with maximum troponin T values in the
higher range, relatively low LVEF baseline and a significant decline
in LVEF. d Patient with maximum troponin T values in the lower
range, relatively high LVEF baseline and no significant decline in
LVEF
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in various clinical trials for patients treated with anthra-
cyclines and trastuzumab. High peak troponin T levels
were proved to be predictive for this high sensitivity
towards trastuzumab induced LVEF decline. The sensi-
tivity analysis demonstrated that the concentration of tro-
ponin T at 21 days after the last anthracycline dose is
predictive of sensitivity to trastuzumab-induced car-
diotoxicity. In addition, the baseline value of LVEF
showed to be moderately positive related to the EC50
parameter, indicating that patients with a low LVEF
baseline tend to be more sensitive to trastuzumab-induced
LVEF decrease.
Repeated NT-proBNP measurements were not inte-
grated in the model, since NT-proBNP showed high vari-
ability. However, some patients experienced high relative
increases of NT-proBNP, approximately 27 weeks after
their nadir of the LVEF value. An increment in NT-
proBNP could therefore possibly be a delayed effect of a
prior decline in LVEF, which could be a sign of other
cardiac comorbidities or a forecast of development of
congestive heart failure. However, early time course data
for NT-proBNP, during anthracycline treatment, was
lacking for most patients, which could be a reason why NT-
proBNP was not identified as an early cardiac biomarker in
this cohort. Additionally, NT-proBNP baseline concentra-
tions were not significantly related to anthracycline-in-
duced troponin T increase nor to LVEF decline during
trastuzumab treatment.
Age, cardiac history and interval between anthracycline
treatment and initiation of trastuzumab treatment have been
previously reported as risk factors for trastuzumab-induced
cardiotoxicity [28]. In addition, age and pre-existing car-
diac disease have been related to anthracycline-induced
cardiotoxicity [29]. In this analysis none of these factors
could be identified as covariates influencing either trastu-
zumab-induced cardiotoxicity or anthracycline-induced
cardiotoxicity. This could be related to in- and exclusion
criteria of the study, since only patients with favorable
cardiac history and relatively low age were included, with a
maximum age of 69 years and only 13% of patients being
older than 60 years. In addition, for only 6% of patients the
length of the interval between end of anthracycline and
initiation of trastuzumab treatment was longer than
30 days, explaining why time between treatments could not
be identified as a covariate in this analysis. Patients in this
study were randomized to receive candesartan or placebo,
initiated on the first day of trastuzumab treatment. There-
fore, we do not expect that the randomization affects the
anthracycline-troponin T model. Candesartan showed no
cardio-protective effects in the original study. Neverthe-
less, to evaluate potential differences between candesartan
and placebo for the trastuzumab-LVEF model, treatment
group was evaluated as a covariate on the EC50 and found
not significantly different. In addition, no differences in
parameter estimates or model fit were seen when the tras-
tuzumab-LVEF model was evaluated for each treatment
group separately.
The biomarker models were not estimated simultane-
ously. However, anthracyclines induce troponin T release
by damaging cardiac cells, where trastuzumab is hypoth-
esized to cause functional changes in contractile proteins,
not associated with cell damage or troponin T changes
[5–7]. Therefore, we do not expect that the LVEF changes
affect the estimation of the anthracycline-troponin T
model. In addition, we used the peak troponin T concen-
tration as a covariate, because the amount of troponin T is
expected to be a marker for the amount of damage caused
by anthracyclines.
The established models can help evaluate the feasibility
of using a cardiac biomarker (e.g. troponin T) to identify
patients at risk of trastuzumab-induced LVEF decline.
However, clinical applicability is challenged by unstan-
dardized analytical assays for determination of cardiac
biomarkers and algorithms to calculate LVEF, definition of
the optimal sampling time point, identification of a cut-off
value and subsequently determination of a proper strategy
in case of identification of an abnormal cardiac value. In
addition, subclinical LV dysfunction can be estimated
using alternative methods, such as determination of LV
diastolic dysfunction and myocardial strain. These param-
eters give insight in early changes in LV remodeling and
have been recommended to monitor patients treated with
cardio-toxic anti-cancer drugs [30].
Although prospective validation is warranted, the
developed models can be applied to evaluate cardiac
monitoring strategies, such as previously described for
LVEF [12]. Simulation of troponin T and LVEF profiles
could aid development of adaptive cardiac monitoring
protocols, possibly integrating troponin T as a potential
biomarker and determination of optimal sampling time
points. Risk-stratified protocols could optimize adaptive
dosing in high-risk patients, ensuring maximum possible
exposure to trastuzumab, and reduce amount of LVEF
measurements in low-risk patients.
In conclusion, to our knowledge this is the first PK-PD
analysis that integrated longitudinal data of two cardiac
biomarkers during anthracycline and trastuzumab treat-
ment. In this cohort, changes in NT-proBNP could not be
demonstrated to be related or predictive of anthracycline-
or trastuzumab-induced cardiotoxicity. The analysis iden-
tified maximum troponin T concentration after anthracy-
cline treatment as a significant determinant of subsequent
trastuzumab-induced LVEF decrease.
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